Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexandros Rodolakis

Showing results (151-160 of 183) with videos related to

Pageof 19
Sort By:
European Journal of Obstetrics, Gynecology, and Reproductive Biology|March 13, 2024
Chemotherapy response score as a predictor of survival in ovarian cancer patientsIoannis Rodolakis, Michalis Liontos, Vasilios Pergialiotis, et al.
Gynecologic Oncology|December 8, 2004
Treatment of ovarian germ cell tumors with a 3-day bleomycin, etoposide, and cisplatin regimen: a prospective multicenter studyMeletios A Dimopoulos, Christos Papadimitriou, Georgios Hamilos, et al.
BMC Cancer|September 27, 2006
Four cycles of paclitaxel and carboplatin as adjuvant treatment in early-stage ovarian cancer: a six-year experience of the Hellenic Cooperative Oncology GroupAristotle Bamias, Christos Papadimitriou, Eleni Efstathiou, et al.
Cancers|July 14, 2023
Optimal Time Interval between Neoadjuvant Platinum-Based Chemotherapy and Interval Debulking Surgery in High-Grade Serous Ovarian CancerAngeliki Andrikopoulou, Charalampos Theofanakis, Christos Markellos, et al.
Current Oncology (Toronto, Ont.)|December 13, 2021
What Has Changed in the Management of Uterine Serous Carcinomas? Two Decades of ExperienceMichalis Liontos, Anna Svarna, Charalampos Theofanakis, et al.
Oncology|August 11, 2006
Young age is associated with favorable characteristics but is not an independent prognostic factor in patients with epithelial ovarian cancer: a single institution experienceGeorge Bozas, Meletios A Dimopoulos, Efstathios Kastritis, et al.
Metabolites|September 26, 2021
Increased Fibroblast Growth Factor 21 (FGF21) Concentration in Early Second Trimester Amniotic Fluid and Its Association with Fetal GrowthNikolaos Vrachnis, Savvas Argyridis, Dionysios Vrachnis, et al.
Anticancer Research|April 30, 2022
p16/Ki-67 Dual Staining Is a Reliable Biomarker for Risk Stratification for Patients With Borderline/Mild Cytology in Cervical Cancer ScreeningMaria Magkana, Panagiota Mentzelopoulou, Ekaterini Magkana, et al.
Clinical Case Reports|February 28, 2022
Prolapse of a large pedunculated uterine myomaIoannis K Papapanagiotou, Sofoklis Stavros, Dimitrios-Efthymios Vlachos, et al.
Medical Sciences (Basel, Switzerland)|February 20, 2026
A Deep Learning Approach for Classifying Benign, Malignant, and Borderline Ovarian Tumors Using Convolutional Neural Networks and Generative Adversarial NetworksMaria Giourga, Ioannis Petropoulos, Sofoklis Stavros, et al.
Pageof 19

Showing results (151-160 of 183) with videos related to

Sort By:
Pageof 19
European Journal of Obstetrics, Gynecology, and Reproductive Biology|March 13, 2024
Chemotherapy response score as a predictor of survival in ovarian cancer patientsIoannis Rodolakis, Michalis Liontos, Vasilios Pergialiotis, et al.
Gynecologic Oncology|December 8, 2004
Treatment of ovarian germ cell tumors with a 3-day bleomycin, etoposide, and cisplatin regimen: a prospective multicenter studyMeletios A Dimopoulos, Christos Papadimitriou, Georgios Hamilos, et al.
BMC Cancer|September 27, 2006
Four cycles of paclitaxel and carboplatin as adjuvant treatment in early-stage ovarian cancer: a six-year experience of the Hellenic Cooperative Oncology GroupAristotle Bamias, Christos Papadimitriou, Eleni Efstathiou, et al.
Cancers|July 14, 2023
Optimal Time Interval between Neoadjuvant Platinum-Based Chemotherapy and Interval Debulking Surgery in High-Grade Serous Ovarian CancerAngeliki Andrikopoulou, Charalampos Theofanakis, Christos Markellos, et al.
Current Oncology (Toronto, Ont.)|December 13, 2021
What Has Changed in the Management of Uterine Serous Carcinomas? Two Decades of ExperienceMichalis Liontos, Anna Svarna, Charalampos Theofanakis, et al.
Oncology|August 11, 2006
Young age is associated with favorable characteristics but is not an independent prognostic factor in patients with epithelial ovarian cancer: a single institution experienceGeorge Bozas, Meletios A Dimopoulos, Efstathios Kastritis, et al.
Metabolites|September 26, 2021
Increased Fibroblast Growth Factor 21 (FGF21) Concentration in Early Second Trimester Amniotic Fluid and Its Association with Fetal GrowthNikolaos Vrachnis, Savvas Argyridis, Dionysios Vrachnis, et al.
Anticancer Research|April 30, 2022
p16/Ki-67 Dual Staining Is a Reliable Biomarker for Risk Stratification for Patients With Borderline/Mild Cytology in Cervical Cancer ScreeningMaria Magkana, Panagiota Mentzelopoulou, Ekaterini Magkana, et al.
Clinical Case Reports|February 28, 2022
Prolapse of a large pedunculated uterine myomaIoannis K Papapanagiotou, Sofoklis Stavros, Dimitrios-Efthymios Vlachos, et al.
Medical Sciences (Basel, Switzerland)|February 20, 2026
A Deep Learning Approach for Classifying Benign, Malignant, and Borderline Ovarian Tumors Using Convolutional Neural Networks and Generative Adversarial NetworksMaria Giourga, Ioannis Petropoulos, Sofoklis Stavros, et al.
Pageof 19